Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer

BACKGROUND: Homologous recombination deficiency (HRD) is shown to predict response to DNA-damaging therapies in patients with high-grade serous ovarian cancer (HGSOC); however, changes in HRD during progression remains unknown. METHODS: HRD scores were evaluated in paired primary and/or recurrent HG...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Jai N., Braicu, Ioana, Timms, Kirsten M., Solimeno, Cara, Tshiaba, Placede, Reid, Julia, Lanchbury, Jerry S., Darb-Esfahani, Silvia, Ganapathi, Mahrukh K., Sehouli, Jalid, Ganapathi, Ram N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219476/
https://www.ncbi.nlm.nih.gov/pubmed/30318511
http://dx.doi.org/10.1038/s41416-018-0268-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219476/
https://www.ncbi.nlm.nih.gov/pubmed/30318511
http://dx.doi.org/10.1038/s41416-018-0268-6

Ejemplares similares